⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL115514 | 1.00 | — | — | |
| SCHEMBL29957409 | 0.82 | — | — | |
| SCHEMBL878387 | 0.82 | — | — | |
| SCHEMBL29955436 | 0.78 | KMT2A (0.46) | — | |
| SCHEMBL2600757 | 0.78 | KMT2A (0.46) | — | |
| SCHEMBL23457261 | 0.77 | — | — | |
| SCHEMBL12530511 | 0.77 | — | — | |
| SCHEMBL5321132 | 0.77 | — | — | |
| SCHEMBL21182060 | 0.77 | — | — | |
| SCHEMBL27243807 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122055368-A | PKMYT1 inhibiting compounds and uses thereof | 杭州中美华东制药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-114555615-B | Complex compound | 庄信万丰股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12528798-B2 | Compound for crop protectant | LG CHEM, LTD. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250230137-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250197353-A1 | METHOD OF FORMING BOND BY COUPLING REACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-119899172-A | KIF18A inhibitor and application thereof | 轩竹生物科技股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| CN-115707702-A | Crystal forms of RAD51 inhibitor compounds and uses thereof | 江苏先声药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| CN-115362003-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2022-11-18 | — | — | CN | disclosed |
| US-20220356200-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-11-10 | — | — | US | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-4076741-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2022-10-26 | — | — | EP | disclosed |
| US-20220331304-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4003342-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Constellation Pharmaceuticals, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450005-A | Compounds for the treatment of neurological disorders | 星座制药公司 | 2022-05-06 | — | — | CN | disclosed |